Inhaled CNS Therapeutics

inhaled CNS therapeutics

Inhaled CNS Therapeutics • JCT383F • March 2021  •  US $2,850 


Delivering drugs to the central nervous system presents unique challenges. But drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics across the blood-brain barrier to the CNS. Pulmonary delivery to the deep lung can have favorable pharmacokinetics. And inhaled delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. These potential advantages have spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis indicates that inhaled CNS administration is well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and commercialization of CNS therapeutic drugs.


Dual chamber syringes & injectors

dual chamber syringes & injectors


          Order Online


What You Will Learn

• Analyzes and evaluates systemic inhaled drug therapeutics for CNS disorders and diseases and assesses the market potential for existing and probable future products
• Evaluates drug technologies and market development issues
• Provides detailed assessments of CNS therapeutic market segments, market demographics, and business strategies
• Charts product sales data, market share, and forecasts to 2012
• Profiles sector companies, their product development activities, business strategies, and corporate alliances and affiliations
• Assesses the importance of alliances and partnerships on future CNS therapeutic products
• Evaluates the impact of economic, technology, and regulatory factors on Inhaled CNS Therapeutics


Inhaled CNS Therapeutics – Summary of Contents

Executive Summary

Drug Delivery Market Dynamics
The Trend toward Self-Administration
CNS Therapeutic Market Dynamics
Growth in Home Healthcare
Market Drivers
Inhaled Drug Development Factors
Device Design Parameters
Nasal Delivery Pharmacokinetics
Nasal Device Characteristics
Pulmonary Delivery Pharmacokinetics
Pulmonary Device Characteristics
Inhaled CNS Drugs: FDA-Approve Products
Inhaled Drugs for Depression
Inhaled Drugs for Pituitary Hormones
Inhaled Drugs for Migraine
Inhaled Drugs for Pain Management
Inhaled Drugs for Parkinson’s Disease
Inhaled Drugs for Schizophrenia
Inhaled Drugs for Seizures
Development-Stage Drugs
Inhaled Drugs in Development for Depression
Inhaled Drugs in Development for Epileptic Seizures
Inhaled Drugs in Development for Migraine
Inhaled Drugs in Development for Stroke
Inhaled CNS Market Segment Analysis
Alzheimer’s and Dementia
Pain Management
Parkinson’s Disease
Market Factors
FDA Regulations
Clinical Trials
Drug-Device Collaborations
Rx-to-OTC Switching
Impact of Generics

Company Profiles